Have You Or Someone In Your Family Been Diagnosed With Endometriosis?
Did you know that women with endometriosis are at an increased risk of ovarian cancer, and that the link may be having the KRAS-variant gene mutation?
You may be eligible for one of several studies that determines if you have the KRAS-variant and aims to determine the best ways to prevent ovarian cancer for women with endometriosis, potentially by having the fallopian tubes removed.
What we know about the KRAS-variant:
- Associated with advanced endometriosis and infertility.
- Associated with a lifetime risk of breast cancer of > 20%, supporting eligibility for higher-level screening.
- Associated almost always with post-menopausal ovarian cancer, allowing the opportunity for cancer prevention without lifestyle impact.
- The genetic cause of cancer for over 50% of Hereditary Breast and Ovarian Cancer (HBOC) families without other known genetic causes, allowing relatives to be tested for a marker to know if they have inherited risk
The KRAS-variant is the only known genetic difference associated with endometriosis. The latest research indicates the KRAS-variant shows great potential to guide disease prevention and management through its unique interactions with hormones and therapies.
TAKE THE ELIGIBILITY SURVEY
We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study. If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.
MiraKind’s pipeline of planned and ongoing research studies are designed to protect the health of individuals with the KRAS-variant and to help answer the most pressing questions.
Research questions include:
- What are the best endometriosis management strategies for KRAS-variant patients?
- What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence cancer risk for individuals with the KRAS-variant?
- How do individuals with the KRAS-variant respond differently to factors like hormone replacement therapy, birth control, or IVF?
- How can we prevent cancers associated with the KRAS-variant for people who are positive but have never been diagnosed with cancer?